Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US7682612B1 · kind B1 · utility
78Cited by
44References
60Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 9, 1999 |
| Grant date | Mar 23, 2010 |
| Priority date | — |
| Expiry date | Nov 9, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.